Compare TSQ & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | ADCT |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 136.1M |
| IPO Year | 2014 | 2019 |
| Metric | TSQ | ADCT |
|---|---|---|
| Price | $6.29 | $1.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.50 | $7.75 |
| AVG Volume (30 Days) | 62.4K | ★ 878.2K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 12.80% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,380,000.00 | $81,357,000.00 |
| Revenue This Year | $2.22 | N/A |
| Revenue Next Year | $0.48 | $66.49 |
| P/E Ratio | $39.75 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $4.30 | $0.78 |
| 52 Week High | $7.97 | $4.98 |
| Indicator | TSQ | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).